Andrew K. Godwin, PhD - Publications

2000-present
1990-1999
1980-1989

2000-present

Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, Ozcelik H, Glendon G; OCGN, Gerdes AM, Thomassen M, Sunde L, Caligo MA, Laitman Y, Kontorovich T, Cohen S, Kaufman B, Dagan E, Baruch RG, Friedman E, Harbst K, Barbany-Bustinza G, Rantala J, Ehrencrona H, Karlsson P, Domchek SM, Nathanson KL, Osorio A, Blanco I, Lasa A, Benítez J, Hamann U, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, van der Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, van Roozendaal CE; HEBON, Peock S, Cook M, Frost D, Oliver C, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Cole T, Hodgson S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, Buecher B, Léoné M, Bressac-de Paillerets B, Remenieras A, Caron O, Lenoir GM, Sevenet N, Longy M, Ferrer SF, Prieur F; GEMO, Goldgar D, Miron A, John EM, Buys SS, Daly MB, Hopper JL, Terry MB, Yassin Y; Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Staudigl C, Hansen TV, Barkardottir RB, Kirchhoff T, Pal P, Kosarin K, Offit K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deibler H, Fiebig B, Suttner C, Schönbuchner I, Gadzicki D, Caldes T, de la Hoya M, Pooley KA, Easton DF; Georgia Chenevix-Trench; on behalf of CIMBA. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics. 2009 Aug 5. [Epub ahead of print]
Kamat AA, Baldwin M, Urbauer D, Dang D, Nugent E, Han LY, Landen CN, Stone RL, Nick AM, Godwin AK, Karlan B, Simpson JL, Gershenson DM, Schmandt R, Mueller P, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. Accepted, 2009.
Bendoraite A, Knouf MC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial model of carcinogenesis. Gynecologic Oncology. Accepted, 2009.
Cai KQ, Caslini C, Capo-chichi CD, Slater C, Smith ER, Wu H, Klein-Szanto A, Godwin AK, Xu X. Loss of GATA4 and GATA6 Expression Specifies Ovarian Cancer Histological Subtypes and Precedes Neoplastic Transformation of Ovarian Surface Epithelia. PLoS ONE. 2009;4(7):e6454.
Rink L, Skorobogatko Y, Kossenkov A, Belinksy M, Pajak T, Heinrich MC, Ochs M, von Mehren M, Eisenberg B, Godwin AK. Genetic Signatures Indicate Predictable Rapid Response to Imatinib Mesylate in the Treatment of Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics. 2009;8:2172-82.
Capo-chichi CD, Cai KQ, Testa J, Godwin AK, Xiang-Xi Xu. Loss of GATA6 Leads to Nuclear Deformation and Aneuploidy in Ovarian Cancer. Molecular and Cellular Biology. 2009;29:4766-77.
Barker SD, Bale S, Buller A, Das S, Friedman K, Godwin AK, Grody W, Highsmith E, Kant J, Lyon E, Mao R, Monaghan K, Payne D, Pratt V, Roa B, Schrijver I, Shrimpton AE, Spector E, Telatar M, Weck K, Zehnbauer B, Booker J, Kalman LV. Development and Characterization of Reference Materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 Genetic Testing. Journal of Molecular Diagnostics. Accepted 2009.
Belinsky MG, Skorobagatko Y, Rink LA, Pei J, Cai Q-K, Vanderveer L, Riddell D, Merkel E, Tarn C, von Mehren M, Testa J, Godwin AK. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2009;48:886-96.
Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Letrero R, Vaughn DJ, Ciosek SL, Doody DR, Smith L, Weaver J, Albano A, Chen C, Starr JR, Rader D, Godwin AK, Reilly M, Hakonarson H, Schwartz SM, Nathanson KL. Common variation in KITLG and at 5q31.3 proximate to SPRY4 predispose to testicular germ cell cancer. Nature Genetics. 2009;41:811-815.
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009 Apr;3(2):97-137. Epub 2009 Feb 21.
Chen X, Kistler JL, Godwin AK. BRCA1-Associated Proteins: Novel Targets for Breast Cancer Radiation Therapy. Nova Science Publishers, Inc. Forthcoming 2009.
Rink L, Godwin AK. Clinical and Molecular Characteristics of Gastrointestinal Stromal Tumor in the Pediatric and Young Adult Population. Current Oncology Reports. 2009;11:314-321.
Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. Biological significance of prolactin in gynecological cancers. Cancer Research. 2009;69:5226-33.
Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, Godwin AK, Adams GP, Brinton LA. Serum Mullerian Inhibiting Substance and Breast Cancer Risk. JNCI. Accepted 2009.
Wyman, SK, Parkin RK, Mitchell PS, Fritz BR, OÕBriant K, Godwin AK, Urban N, Drescher C, Knudsen B, Tewari M. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS ONE. 2009 Apr 23;4(4):e5311. [Epub]
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Godwin AK. Hereditary Ovarian Cancer: Molecular Genetics, Pathology, Management, and Heterogeneity. Molecular Oncology. 2009 Feb 21;3:97-137.
Tarn C, Godwin AK. Gastrointestinal stromal tumor. Encyclopedia of Cancer. Springer Berlin Heidelberg, Part 7, Page 1217, 2009.
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009 Apr;3(2):97-137. Epub 2009 Feb 21.
Schilder RJ, Pathak HB, Lokshin AE, Holloway,RW, Alvarez RD, Pathak H, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single-agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecologic Oncology. 2009;113:21-27
Howard JH, Frolov A, Tzeng CD, Stewart A, Midzak A, Majmundar A, Godwin AK, Heslin MJ, Bellacosa A, Arnoletti JP. Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer. Cancer Biol Ther. 2009 Jan;8(1):94-100.
Melnikov A, Scholtens D, Godwin A, Levenson V. Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma. Journal of Molecular Diagnostics. [Article]. 2009 Jan;11(1):60-5.
Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. Journal of Proteome Research. [Article]. 2009 Jan;8(1):113-7.
Roussi P, Sherman K, Miller SM, Buzaglo JS, Daly MB, Taylor A, Ross E, Godwin AK. Enhanced counseling for women undergoing BRCA1/2 testing: impact on knowledge and psychological distress- results from a randomized clinical trial. Journal of Psychology & Health, 2009.
Sarkar D, Parkin R, Wyman S, Bendoraite A, Sather C, Delrow J, Godwin AK, Drescher C, Huber W, Gentleman R, Tewari M. Quality assessment and data analysis for microRNA expression arrays. Nucleic Acids Res. 2009 Feb;37(2):e17. Epub 2008 Dec 22.
Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X, kConFab Investigators, AOCS Group, The Swedish BRCA1 and BRCA2 Study Collaborators, Gschwantler-Kaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko Y-D, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T. Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FBL, Rookus MA, Seynaeve C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os, TA, Gille HJ, Blok MJ, HEBON, Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G. (on behalf of the Breast Cancer Association Consortium and the Consortium of Investigators of Modifiers of BRCA1/2). No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res. Treat. 2008 Dec 11. [Epub ahead of print]. NIHMSID #93105
Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle. [Article]. 2008 Oct;7(19):2949-55.
Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, Senie RT, Terry MB for the Breast Cancer Family Registry. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res. Treat. 2008 Aug 14. [Epub ahead of print] Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proceedings of the National Academy of Sciences of the United States of America. [Article]. 2008 Jun;105(24):8387-92.
Patel BB, He AY, Li X-M, Frolov A, Vanderveer L, Slater C, Schilder R, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics & Proteomics. 2008 May-Aug;5(3-4):137-49.
Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecologic Oncology. [Article]. 2008 Jul;110(1):99-109.
Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kampjarvi K, Nevanlinna H, Simard J, Beesley J, Chen XQ, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Bium JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LHM, Greene MH, Rennert G, Leibkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benitez J, Hamann U, Hogervorst FBL, Manders P, Ligtenberg MJL, van den Ouweland AMW, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Paillerets BBD, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D, Easton DF. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. American Journal of Human Genetics. [Article]. 2008 Apr;82(4):937-48.
Chen X, Weaver J, Bove BA, Vanderveer LA, Weil SC, Miron A, Daly MB, Godwin AK. Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet. 2008 May 1;17(9):1336-48.
Zeechini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG, Cavallaro U. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Research. [Article]. 2008 Feb;68(4):1110-8.
Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Research. [Article]. 2008 Feb;68(4):998-1002.
Liang M, Ayanga B, Du S, Godwin AK, Hartsock JK, Evans SC. OvcaI, a candidate gene of the genetic modifier of Tp53, Mop2, affects mouse embryonic lethality. Genes Chromosomes & Cancer. [Article]. 2008 Apr;47(4):315-25.
Fang CY, Miller SM, Bovbjerg DH, Bergman C, Edelson MI, Rosenblum NG, Bove BA, Godwin AK, Campbell DE, Douglas SD. Perceived Stress is Associated with Impaired T-Cell Response to HPV16 in Women with Cervical Dysplasia. Ann Behav Med. 2008 Jan-Feb;35(1):87-96.
Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Research. [Article]. 2007 Sep;67(18):8433-8.
Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. American Journal of Human Genetics. 2007 81:1186-1200.
Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol. 2007 Nov;178(5):1920-4; discussion 4.
Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods in Enzymology. 2007;433:1-25.
Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology. 2007 Aug 1;25(22):3230-7.
Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakubowska A, Lubinski J, Gronwald J, Spurdle AB, KconFab, Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, Andrulis IL, Ilyushik E, Glendon G, Devilee P, Vreeswijk MPG, Vasen HFA, Borg A, Backenhorn K, Struewing JP, Greene MH, Neuhausen SL, Rebbeck TR, Nathanson K, Domchek S, Wagner T, Garber JE, Szabo C, Zikan M, Foretova L, Olson JE, Sellers TA, Lindor N, Ll HN, Tommiska J, Aittomaki K, Hamann U, Rashid MU, Torres D, Simard J, Durocher F, Guenard F, Lynch HT, Isaacs C, Weitzel J, Olopade OI, Narod S, Daly MB, Godwin AK, Tomlinson G, Easton DF, Chenevix-Trench G, Antoniou AC. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiology Biomarkers & Prevention. [Article]. 2007 Jul;16(7):1416-21.
Tchou J, Ward MR, Volpe P, Palma MD, Medina CA, Sargen M, Sonnad SS, Godwin AK, Daly M, Winchester DJ, Garber J, Weber BL, Domchek S, Nathanson KL. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clinical Breast Cancer. [Article]. 2007 Jun;7(8):627-33.
Page RE, Klein-Szanto AJP, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, Bassi DE. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cellular Oncology. [Article]. 2007;29(4):289-99.
Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. [Article]. 2007 Apr;109(7):1323-30.
Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, DiRenzo J. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Research. [Article]. 2007 Jan;67(2):501-10.
Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology. [Article]. 2007 Jan;31(1):121-8.
Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, Xu XX. Prominent expression of metalloproteinases in early stages of ovarian turnorigenesis. Molecular Carcinogenesis. [Article]. 2007 Feb;46(2):130-43.
Petrocca F, Iliopoulos D, Qin HYR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, Croce CM. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer Cancer Research. 2006 Nov;66(21):10287-91.
Pan ZZ, Bruening W, Godwin AK. Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. International Journal Of Oncology. 2006 Nov;29(5):1201-5.
Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecologic Oncology. [Article]. 2006 Nov;103(2):719-28.
Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC; kConFab Investigators, Ontario Cancer Genetics Network Investigators, Whittemore, A.S. BRCA1 and BRCA2 mutation carriers, oral contraceptive use and breast cancer risk before age 50. Cancer Epidemiology, Biomarkers & Prevention. [Article]. 2006 Oct; 15(10):1863-1870.
Chen XW, Truong TTN, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK. Intronic alterations in BRCA1 and BRCA2: Effect on mRNA splicing fidelity and expression. Human Mutation. 2006 May;27(5):427-35.
He F, Fenner BJ, Godwin AK, Kwang J. White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination. Journal Of Virology. 2006 Apr;80(8):3884-92.
Azizi AA, Gelpi E, Yang JW, Rupp B, Godwin AK, Slater C, Slavc I, Lubec G. Mass spectrometric identification of serine hydrolase OVCA2 in the medulloblastoma cell line DAOY. Cancer Letters. 2006 Sep;241(2):235-49.
McGuire V, John EM, Felberg A, Haile RW, Boyd NF, Thomas DC, Jenkins MA, Milne RL, Daly MB, Ward J, Terry MB, Andrulis IL, Knight JA, Godwin AK, Giles GG, Southey M, West DW, Hopper JL, Whittemore ASGAkI. No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages < 50 years. Cancer Epidemiology Biomarkers & Prevention. 2006 Aug;15(8):1565-7.
Prowse AH, Manek S, Varma R, Liu JS, Godwin AK, Maher ER, Tomlinson IPM, Kennedy SH. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. International Journal Of Cancer. 2006 Aug;119(3):556-62.
Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK. Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms. Cancer Res. 2006 May 15;66(10):5477-86.
Colilla S, Kantoff PW, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Brown M, Weber BL, Rebbeck TR. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis. 2006 Mar;27(3):599-605.
Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology Biomarkers & Prevention. 2006 Jan;15(1):76-9.
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors. Clinical Colorectal Cancer, 6, Suppl. 2006;1:S7-S17.
Chen X, Arciero C, Godwin AK. BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. Expert Review of Anticancer Therapy. 2006;6:187-196.
Miller SM, Daly MB, Sherman KA, Fleisher L, Buzaglo JS, Stanton L, Godwin AK, Scarpato J. Psychosocial processes in genetic risk assessment for breast cancer. III. Applications to Specific Genetic Conditions. In Individuals, Families, and the New Era of Genetics: Biopsychosocial Perspectives. Edited by Miller SM, McDaniel SH, Rolland, JS, Feetham SL. (W.W. Norton & Company, Inc.: New York, NY). Chapter 10, pp. 274-319, 2006.
Miller SM, Roussi P, Daly MB, Buzaglo JS, Sherman K, Godwin AK, Balshem A, Atchison ME. Enhanced counseling for women undergoing BRCA1/2 testing: impact on subsequent decision making about risk reduction behaviors. Health Educ Behav. 2005;Oct;32(5):654-67.
Capo-Chichi CD, Rula ME, Smedberg JL, Vanderveer L, Parmacek MS, Morrisey EE, Godwin AK, Xu XX. Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. Developmental Biology. 2005;286(2):574-86.
Schilder R, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a gynecologic oncology group study. Clinical Cancer Research. 2005 Aug 1;11(15):5539-48.
Tarn C, Merkel E, Canutescu AA, Shen W, Skorobogatko Y, Heslin MJ, Eisenberg B, Birbe R, Patchefsky A, Dunbrack R, Arnoletti JP, Von Mehren M, Godwin AK. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: Therapeutic implications through protein modeling. Clinical Cancer Research. 2005;11(10):3668-77.
Yang WL, Roland IH, Godwin AK, Xu XX. Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. Oncogene. 2005 Jul;24:7991-8002.
Guo S, Hakimi MA, Baillat D, Chen X, Farber MJ, Klein-Szanto AJP, Cooch NS, Godwin AK, Shiekhattar R. Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. Cancer Research. 2005;65(8):3011-6.
Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer. 2005;5(1):64.
Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. Familial cancer associated with a polymorphism in ARLTS1. New England Journal of Medicine. 2005 Apr 21;352(16):1667-76.
Sarti M, Sevignani C, Calin GA, Aqeilan R, Shimizu M, Pentimalli F, Picchio MC, Godwin A, Rosenberg A, Drusco A, Negrini M, Croce CM. Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clinical Cancer Research. 2005 Jan 15;11(2):806-13.
Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand JM, Lessin S, Seykora JT. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. Journal of Cutaneous Pathology. 2005 Feb;32(2):125-30.
Smith-Beckerman DM, Fung KW, Williams KE, Auerspeg N, Godwin AK, Burlingame AL. Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer. Molecular and Cellular Proteomics. 2005;4(2):156-68.
Tarn C, Godwin AK. Molecular research directions in the management of GIST tumors. Current Treatment Options in Oncology. 2005;6:473-486.
Pan Z-Z, Godwin, AK. Oncogenes. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Edited by RA Meyers, Second Edition, Volume 9. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp. 435-495, 2005.
Bui CT, Nicolas E, Sallmann G, Chiotis M, Lambrinakos A, Rees K, Trounce I, Cotton RGH, Hancock L, Godwin AK, Yeung AT. Enzymatic and chemical cleavage methods to identify genetic variation. Molecular Diagnostics (edited by G. Patrinos and W. Ansorge), Elsevier Academic Press, Chapter 5, pp. 41-54, 2005.
Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li Y-S, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman B, Crowell JA, Kopelovich Knudson AG. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biology and Therapy. 2004 Dec;3(12):1313-21.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
Pinte S, Guerardel C, Deltour-Balerdi S, Godwin AK, Leprince D. Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1. Oncogene. 2004 May;23(22):4023-31.
Yang WL, Godwin AK, Xu XX. Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: Molecular basis linking ovulation and cancer risk. Cancer Research. 2004 Feb;64(4):1534-40.
Ozols RF, Bookman M, Connolly D, Daly MB, Godwin AK, Schilder R, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19-24.
Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer. 2003 Dec;98(12):2607-23.
Dong YS, Hakimi MA, Chen XW, Kumaraswamy E, Cooch NS, Godwin AK, Shiekhattar R. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Molecular Cell. 2003 Nov;12(5):1087-99.
Burrows JF, Chanduloy S, McIlhatton MA, Nagar H, Yeates K, Donaghy P, Price J, Godwin AK, Johnston PG, Russell SHE. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. Journal of Pathology. 2003 Dec;201(4):581-8.
Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE, Godwin AK, Negrini M, Croce CM. The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proceedings of the National Academy of Sciences of the United States of America. 2003 Sep;100(20):11517-22.
Capo-Chichi CD, Roland IH, Vanderveer L, Bao RD, Yamagata T, Hirai H, Cohen C, Hamilton TC, Godwin AK, Xu XX. Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Research. 2003 Aug;63(16):4967-77.
Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan Z-Z, Favorova O, Fletcher J, von Mehren M, Eisenberg B, Godwin AK. Response markers and the molecular mechanisms of action of gleevec in gastrointestinal stromal tumors (GISTs). Mol Cancer Ther. 2003 Aug;2(8):699-709.
Prowse A, Schultz DC, Guo S, Vanderveer L, Dangel J, Bove B, Cairns P, Daly M, Godwin AK. Identification of a novel splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma-prone kindred. J Med Genet. 2003 Aug;40(8):102-8.
Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Mascillo V, d'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proceedings of the National Academy of Sciences of the United States of America. 2003 May 13;100(10):5956-61.
Wagner Costalas J, Itzen M, Malick J, Babb JS, Bove B, Godwin AK, Daly MB. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet. 2003 May 15;119C(1):11-8.
Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, Suga M, Matsumoto M, Wong AJ. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Science. 2003 Jan;94(1):50-6.
Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the Synuclein gamma Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma. Cancer Res. 2003 Feb 1;63(3):664-73.
Frolov A, Godwin AK, Favorova OO. Differential gene expression analysis by DNA microarrays technology and its application in molecular oncology. Mol Biol. 2003;37(4):573-584.
Ochs M and Godwin AK. Microarrays in cancer: research and applications. BioTechniques. 2003;34:4-15.
Ochs M, Godwin AK. Introduction. Microarrays in Cancer (Supplement to BioTechniques). p. 1, 2003, Guest Editor.
Prowse A, Frolov A, Godwin AK. The genetics of ovarian cancer. American Cancer Society Atlas of Clinical Oncology. B.C. Decker Inc., Publisher, pp. 49-82, 2003.
Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem. 2002 Sep 20;277(38):35050-60.
Smedberg JL, Smith ER, Capo-Chichi CD, Frolov A, Yang DH, Godwin AK, Xu XX. Ras/MAPK Pathway Confers Basement Membrane Dependence upon Endoderm Differentiation of Embryonic Carcinoma Cells. J Biol Chem. 2002 Oct 25;277(43):40911-8.
Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer. 2002 Oct 15;95(8):1802-15.
Broccoli D, Godwin AK. Telomere length changes in human cancer. In: Boultwood J, Fidler C, editors. Molecular analysis of cancer. Totowa, N.J.: Humana Press; 2002. p. 271-8.
Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, Tnani M, Holgado-Madruga M, Moscatello DK, Wong AJ. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene. 2002 Aug 1;21(33):5038-46.
Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey MC, van Orsouw NJ, Venter DJ, Vijg J, Whittemore AS, Cooperative Family Registry Breast. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Human Mutation. 2002;20(1):65-73.
Frolov A, Prowse AH, Vanderveer L, Bove B, Wu H, Godwin AK. DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer. 2002 Nov;35(3):232-41.
Yang DH, Smith ER, Cohen C, Wu H, Patriotis C, Godwin AK, Hamilton TC, Xu XX. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer. 2002 May 1;94(9):2380-92.
Prowse AH, Vanderveer L, Milling SW, Pan ZZ, Dunbrack RL, Xu XX, Godwin AK. OVCA2 is downregulated and degraded during retinoid-induced apoptosis. Int J Cancer. 2002 May 10;99(2):185-92.
Roberts D, Williams SJ, Cvetkovic D, Weinstein JK, Godwin AK, Johnson SW, Hamilton TC. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol. 2002 Jan;21(1):11-9.
Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. American Journal of Pathology. 2002 Feb;160(2):441-7.
Raftogianis RB, Godwin AK. The impact of protein interaction technologies on cancer biology and pharmacogenetics, In Protein-Protein Interactions: A Molecular Cloning Manual. Ed. E Golemis. The Cold Spring Harbor, pp. 15-36, 2002.
Bove B, Dunbrack R, Godwin AK. BRCA1, BRCA2, and hereditary breast cancer. Breast Cancer: Prognosis, Treatment and Prevention. Ed. J Pasqualini. Marcel Dekker Inc., Publisher Chapter 19, pp. 555-624, 2002.
Broccoli D and Godwin AK. Telomere length changes in human cancer. (From Methods in Molecular Medicine, vol. 68: Molecular Analysis of Cancer. Edited by J. Boultwood and C. Fidler. Humana Press Inc., Totowa, NJ.) Methods Mol Med. 2002;68:271-278.
Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001 Dec 15;10(26):3001-7.
Lee SB, Kim SH, Bell DW, Wahrer DCR, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA. Destabilization of CHK2 by a missense mutation associated with Li- Fraumeni syndrome. Cancer Research. 2001 Nov 15;61(22):8062-7.
Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX. Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells. J Biol Chem. 2001 Dec 14;276(50):47303-10.
Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):955-60.
Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001 Jul 15;61(14):5420-4.
Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dube MP, Kieback DG, Narod SA. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct;11(7):635-8.
Guerardel C, Deltour S, Pinte S, Monte D, Begue A, Godwin AK, Leprince D. Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J Biol Chem. 2001 Feb 2;276(5):3078-89.
Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci. 2000 Dec;113 Pt 24:4577-85.
Kulinski J, Besack D, Oleykowski CA, Godwin AK, Yeung AT. CEL I enzymatic mutation detection assay. Biotechniques. 2000 Jul;29(1):44-8.
Bruening W, Giasson BI, Klein-Szanto A, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 2000 May 1;88(9):2154-63.
Top

1990-1999

Riccio A, Aaltonen LA, Godwin AK, Loukola A, Percesepe A, Salovaara R, Masciullo V, Genuardi M, Paravatou-Petsotas M, Bassi DE, Ruggeri BA, Klein-Szanto AJ, Testa JR, Neri G, Bellacosa A. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nature Genet. 1999 Nov;23(3):266-8.
Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, Godwin AK. Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Research. 1999 Oct 1;59(19):4973-83.
Hirai H, Taguchi T, Godwin AK. Genomic differentiation of 18S ribosomal DNA and beta-satellite DNA in the hominoid and its evolutionary aspects. Chromosome Research. 1999;7(7):531-40.
Dangel J, Wagner-Costalas J, Bove B, Vanderveer L, Itzen M, Daly M, Godwin AK. Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer. Human Mutation. 1999 Dec;14(6):545.
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer. 1999 Sep;81(1):179-83.
Rebbeck TR, Kantoff PN, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. American Journal of Human Genetics. 1999 May;64(5):1371-7.
Kruk PA, Godwin AK, Hamilton TC, Auersperg N. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecologic Oncology. 1999 May;73(2):229-36.
Abdollahi A, Getts LA, Sonoda G, Miller PD, Taguchi T, Godwin AK, Testa JR, Hamilton TC. Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells. J Soc Gynecol Invest. 1999 Jan-Feb;6(1):32-40.
Oleykowski CA, Mullins CRB, Godwin AK, Yeung AT. Mutation detection using a novel plant endonuclease. Nucleic Acids Research. 1998 Oct 15;26(20):4597-602.
Schultz DC, Balasara BR, Testa JR, Godwin AK. Cloning and localization of a human diphthamide biosynthesis- like protein-2 gene, DPH2L2. Genomics. 1998 Sep 1;52(2):186-91.
Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King MC, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APC I1307K allele and breast cancer risk. Nature Genet. 1998 Sep;20(1):13-4.
Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA, and the Hereditary Ovarian Cancer Clinical Study Group (A.K. Godwin et al.). Oral contraceptives and the risk of hereditary ovarian cancer. New England Journal of Medicine. 1998 Aug 13;339(7):424-8.
Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, Ponder BAJ, Weber B, Devilee P, Borg A, Narod SA, Goldgar D. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: Results of an international study. American Journal of Human Genetics. 1998 Jun;62(6):1381-8.
Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade OI, Moslehi R, Liede A, Futreal PA, Weber BL, Lenoir GM, Lynch HT, Narod SA. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20;90(10):761-6.
Hamilton TC, Johnson SW, Godwin, AK. Molecular biology of gynecologic malignancies. In: Diagnostic and Therapeutic Advances in Gynecologic Oncology, Ozols, R.F. (ed). Kluwer Academic Publishers, Boston. Cancer Treat Res. 1998;95:103-114.
Lynch HT, Casey MJ, Lynch J, White TE, Godwin AK. Genetics and ovarian carcinoma. Seminars in Oncology (Ozols, ed). 1998;25:265-280.
Petrukhin L, Dangel J, Vanderveer L, Costalas J, Bellacosa A, Grana G, Daly M, Godwin AK. The I1307K APC mutation does not predispose to colorectal cancers in Jewish Ashkenazi breast and breast/ovarian cancer kindreds. Cancer Research. 1997 Dec 15;57(24):5480-4.
Monaco C, Negrini M, Sozzi G, Veronese ML, Vorechovsky I, Godwin AK, Croce CM. Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. Genomics. 1997 Dec 1;46(2):217-22.
Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Yakushiji M, Testa JR. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer. 1997 Dec;20(4):320-8.
Abdollahi A, Godwin AK, Miller PD, Getts LA, Schultz DC, Taguchi T, Testa JR, Hamilton TC. Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Research. 1997 May 15;57(10):2029-34.
Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G, Testa JR, Hamilton TC. Identification of a zinc-finger gene at 6q25: A chromosomal region implicated in development of many solid tumors. Oncogene. 1997 Apr 24;14(16):1973-9.
Sonoda G, du Manoir S, Godwin AK, Bell DW, Liu Z, Hogan M, Yakushiji M, Testa JR. Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization. Genes Chromosomes Cancer. 1997 Feb;18(2):115-25.
Godwin AK, Schultz DC, Hamilton TC, Knudson AG. Oncogenes and tumor suppressor genes gynecologic malignancies. In Hoskins WJ, Perez CA, Young RC. (eds): Gynecologic Oncology: Principles and Practice, pp. 107-148,1997.
Rebbeck TR, Walker AH, Phelan CM, Godwin AK, Buetow KH, Garber JE, Narod SA, Weber BL. Defining etiologic heterogeneity in breast cancer using genetic biomarkers. Progress in Clinical and Biological Research. 1997;396:53-61.
Dyck HG, Hamilton TC, Godwin AK, Lynch HT, MainesBandiera S, Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer. International Journal of Cancer. 1996 Dec 20;69(6):429-36.
Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20.
O’Dwyer PJ, Perez RP, Yao KS, Godwin AK, Hamilton TC. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. Biochem Pharmacol. 1996 Jul 12;52(1):21-7.
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, WagnerCostalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, Garber JE. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov;2(11):1179-83.
Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Research. 1996 Aug 1;56(15):3409-14.
Rebbeck TR, Godwin AK, Buetow KH. Variability in loss of constitutional heterozygosity across loci and among individuals: Association with candidate genes in ductal breast carcinoma. Molecular Carcinogenesis. 1996 Nov;17(3):117-25.
Berman DB, WagnerCostalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA 1 mutation in breast- ovarian cancer families: A genetic study of 15 185delAG- mutation kindreds. American Journal of Human Genetics. 1996 Jun;58(6):1166-76.
Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, ShattuckEidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genet. 1996 May;13(1):123-5.
Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Research. 1996 May 1;56(9):1997-2002.
Yao KS, Godwin AK, Johnson C, Odwyer PJ. Alternative splicing and differential expression of DT- diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. Cancer Research. 1996 Apr 15;56(8):1731-6.
HolgadoMadruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature. 1996 Feb 8;379(6565):560-4.
Hamilton TC, Miller PD, Getts LA, Godwin AK. The use of retroviral-like elements to detect genetic differences between normal and transformed rat ovarian surface epithelial cells. Ovarian Cancer 4, edited by F Sharp, T Blackett, J Berek. Chapman & Hall, London, 1996.
Hamilton TC, Godwin AK, Ozols RF. Carcinogenesis in the ovary. Cancer de I"ovaire, eds. J Dauplat, J-P Guastalle. Paris (France), Arnette Blackwell SA, pp. 21-38, 1996.
Beesley JS, Ferry KV, Johnson SW, Godwin AK, Hamilton TC. The biology of female cancers. Ovarian cancer: Biological basis of Therapy. Eds. SP Langdon, W Miller, A. Berchuck. CRC Press, Boca Raton, FL. pp. 153-166, 1997.
Boente MP, Hamilton TC, Godwin AK, Buetow K, Kohler MF, Hogan WM, Berchuck A, Young RC. Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Current Problems in Cancer. 1996;20(2):83-137.
Hamilton TC, Yao KS, Beesley JS, Johnson SW, Godwin AK, O'Dwyer PJ, Ozols RF. The relationship and regulation of glutathione in cancer cells resistant to chemotherapy. In: N Vermeulen, G Mulder, H Nieuwenhuyse, W Peters, P van Bladeron (eds.), Glutathione S-transferases: Structure, function and clinical implications. Chap. 16, pp. 173-185, Taylor and Francis, NY, 1996.
Schroder CP, Godwin AK, O'Dwyer PJ, Tew KW, Hamilton TC, Ozols, RF. Glutathione and drug resistance. Cancer Invest. 1996;14:158-168.
Godwin AK, Miller PD, Getts LA, Jackson K, Sonoda G, Schray KJ, Testa JR, Hamilton TC. Retroviral-Like Sequences Specifically Expressed in the Rat Ovary Detect Genetic-Differences between Normal and Transformed Rat Ovarian Surface Epithelial-Cells. Endocrinology. 1995 Oct;136(10):4640-9.
Yao KS, Godwin AK, Johnson SW, Ozols RF, Odwyer PJ, Hamilton TC. Evidence for Altered Regulation of Gamma-Glutamylcysteine Synthetase Gene-Expression among Cisplatin-Sensitive and Cisplatin-Resistant Human Ovarian-Cancer Cell-Lines. Cancer Research. 1995 Oct 1;55(19):4367-74.
Kruh GD, Gaughan KT, Godwin A, Chan A. Expression Pattern of Mrp in Human Tissues and Adult Solid Tumor-Cell Lines. Journal of the National Cancer Institute. 1995 Aug 16;87(16):1256-8.
Moscatello DK, Holgadomadruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. Frequent Expression of a Mutant Epidermal Growth-Factor Receptor in Multiple Human Tumors. Cancer Research. 1995 Dec 1;55(23):5536-9.
Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. International Journal of Cancer.1995 Aug 22;64(4):280-5.
Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Research. 1995 May 15;55(10):2150-7.
Auersperg N, Mainesbandiera S, Booth JH, Lynch HT, Godwin AK, Hamilton TC. Expression of 2 Mucin Antigens in Cultured Human Ovarian Surface Epithelium - Influence of a Family History of Ovarian- Cancer. Am J Obstet Gynecol. 1995 Aug;173(2):558-65.
Salazar H, Godwin AK, Getts LA, Testa JR, Daly M, Rosenblum N, Hogan M, Ozols RF, Hamilton TC. Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer. In Ovarian Cancer 3, edited by F Sharp, P Mason, A Blackett, J Berek. Chapman & Hall, London, pp. 145-156, 1995.
Hamilton TC, Johnson SW, Godwin AK, Bookman MA, O'Dwyer PJ, Hamaguchi K, Jackson K, Ozols RF. Drug resistance in ovarian cancer and potential for its reversion. In Ovarian Cancer 3, edited by F Sharp, P. Mason, A Blackett, J Berek. Chapman & Hall, London, pp. 203-213, 1995.
Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC. Relationship between Platinum-DNA Adduct Formation and Removal and Cisplatin Cytotoxicity in Cisplatin-Sensitive and Cisplatin-Resistant Human Ovarian-Cancer Cells. Cancer Research. 1994 Nov 15;54(22):5911-6.
Godwin AK, Vanderveer L, Schultz DC, Lynch HT, Altomare DA, Buetow KH, Daly M, Getts LA, Masny A, Rosenblum N, Hogan M, Ozols RF, Hamilton TC. A Common Region of Deletion on Chromosome 17q in Both Sporadic and Familial Epithelial Ovarian-Tumors Distal to Brcai. American Journal of Human Genetics. 1994 Oct;55(4):666-77.
O’Dwyer PJ, Yao KS, Ford P, Godwin AK, Clayton M. Effects of Hypoxia on Detoxicating Enzyme-Activity and Expression in Ht29 Colon Adenocarcinoma Cells. Cancer Research. 1994 Jun 15;54(12):3082-7.
Testa JR, Getts LA, Salazar H, Liu ZM, Handel LM, Godwin AK, Hamilton TC. Spontaneous Transformation of Rat Ovarian Surface Epithelial- Cells Results in Well to Poorly Differentiated Tumors with a Parallel Range of Cytogenetic Complexity. Cancer Research. 1994 May 15;54(10):2778-84.
Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC. Role of Platinum-DNA Adduct Formation and Removal in Cisplatin Resistance in Human Ovarian-Cancer Cell-Lines. Biochem Pharmacol. 1994 Feb 11;47(4):689-97.
Boente MP, Godwin AK, Hogan WM. Screening, imaging, and early diagnosis of ovarian cancer. Clin Obstet Gynecol. 1994;37:377-391.
Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Research. 1993;53(21):5225-32.
Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. Journal of Immunology. 1993;151(5):2877-86.
Yao KS, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Research. 1993;53(16):3662-6.
Ranganathan S, Walsh ES, Godwin AK, Tew KD. Cloning and Characterization of Human Colon Glyoxalase-I. J Biol Chem. 1993 Mar 15;268(8):5661-7.
Godwin AK, Testa JR, Hamilton TC. The Biology of Ovarian-Cancer Development. Cancer. 1993 Jan 15;71(2):530-6.
Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton TC, Godwin AK. Transformation of Rat Ovarian Epithelial and Rat-1 Fibroblast Cell-Lines by Rast24 Does Not Influence Cisplatin Sensitivity. Cancer Research. 1993 Aug 15;53(16):3771-5.
Perez RP, Godwin AK, Handel LM, Hamilton TC. A Comparison of Clonogenic, Microtetrazolium and Sulforhodamine-B Assays for Determination of Cisplatin Cytotoxicity in Human Ovarian-Carcinoma Cell-Lines. Eur J Cancer. 1993;29A(3):395-9.
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, and Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 1992 Oct 1;89(19):9267-92.
Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC. Growth-Regulation of Ovarian-Cancer. Hematol Oncol Clin North Am. 1992 Aug;6(4):829-41.
Godwin AK, Meister A, O'Dwyer PJ, Chin Shiou H, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(7):3070-4.
Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC. Spontaneous Transformation of Rat Ovarian Surface Epithelial- Cells - Association with Cytogenetic Changes and Implications of Repeated Ovulation in the Etiology of Ovarian-Cancer. J Natl Cancer Inst. 1992 Apr 15;84(8):592-601.
Habib, GM, Rajagopalan, S, Godwin, AK, Lebovitz, RM and Lieberman, MW. The same gamma-glutamyl transpeptidase RNA species is expressed in fetal liver, hepatic carcinomas and rasT24-transformed rat liver epithelial cells. Molecular Carcinogenesis. 1992;5(1):75-80.
Godwin AK, Hamilton TC, Knudson AG. Oncogenes and anti-oncogenes in gynecologic malignancies. In Hoskins WJ, Perez CA, Young RC. (eds): Gynecologic Oncology: Principles and Practice. pp 87-116, 1992.
Speicher LA, Sheridan VR, Godwin AK, Tew KD. Resistance to the Antimitotic Drug Estramustine Is Distinct from the Multidrug Resistant Phenotype. Br J Cancer. 1991 Aug;64(2):267-73.
Perez RP, Godwin AK, Hamilton TC, Ozols R. Ovarian cancer biology. Semin Oncol. 1991;18:186-204.
Godwin AK, Lieberman MW. Elevation of Glucose Transporter, C-Myc, and Transin Rna Levels by Ha-Rast24 Is Independent of Its Effect on the Cell-Cycle. Molecular Carcinogenesis. 1991;4(4):275-85.
Godwin AK, Lieberman MW. Early and Late Responses to Induction of Rast24 Expression in Rat-1 Cells. Oncogene. 1990 Aug;5(8):1231-41.
Top

1980-1989

Seyama T, Godwin AK, DiPietro M, Winokur TS, Lebovitz RM, Lieberman MW. In vitro and in vivo regulation of liver epithelial cells carrying a metallothionein-rasT24 fusion gene. Molecular Carcinogenesis. 1988;1(2):89-95.
Li Y, Seyama T, Godwin AK, Winokur TS, Lebovitz RM, Lieberman MW. MTrasT24, a metallothionein-ras fusion gene, modulates expression in cultured rat liver cells of two genes associated with in vivo liver cancer. Proc Natl Acad Sci USA. 1988 Jan;85(2):344-8.
Reynolds VL, Lebovitz RM, Warren S, Hawley TS, Godwin AK, Lieberman MW. Regulation of a metallothionein-rasT24 fusion gene by zinc results in graded alterations in cell morphology and growth. Oncogene. 1987;1(3):323-30.
MacArthur CA, Ramabhadran R, Godwin AK, Lebovitz RM, Lieberman MW. Chemical carcinogens induce cadmium resistance and activate metallothionein genes in cadmium sensitive S49 mouse cells. Carcinogenesis. 1985 Jun;6(6):887-92.
Top